The T-CEA score: a useful prognostic indicator based on postoperative CEA and pathological T4 levels for patients with stage II-III colorectal cancer

被引:2
作者
Sonoda, Hiromichi [1 ]
Yamada, Takeshi [1 ]
Matsuda, Akihisa [1 ]
Yokoyama, Yasuyuki [2 ]
Ohta, Ryo [2 ]
Shinji, Seiichi [1 ]
Yonaga, Kazuhide [1 ]
Iwai, Takuma [1 ]
Takeda, Kohki [1 ]
Ueda, Koji [1 ]
Kuriyama, Sho [1 ]
Miyasaka, Toshimitsu [1 ]
Kanaka, Shintaro [1 ]
Taniai, Nobuhiko [2 ]
Yoshida, Hiroshi [1 ]
机构
[1] Nippon Med Sch, Dept Gastrointestinal Hepatobiliary Pancreat Surg, 1-1-5 Sendagi,Bunkyo Ku, Tokyo 1138603, Japan
[2] Nippon Med Sch, Dept Gastrointestinal Hepatobiliary Pancreat Surg, Musashikosugi Hosp, Tokyo, Japan
关键词
T-CEA score; Postoperative CEA; Pathological T4; Prognostic score; Stage II-III colorectal cancer; COLON-CANCER; PREDICTING SURVIVAL; RECURRENCE; GUIDELINES;
D O I
10.1007/s00595-023-02644-6
中图分类号
R61 [外科手术学];
学科分类号
摘要
PurposeTo investigate a prognostic score for stage II-III colorectal cancer (CRC) based on post-CEA and pT4 levels.MethodsTwo cohorts of stage II-III CRC patients who underwent curative surgery between 2011 and 2017 were included. The prognostic score (T-CEA score) was calculated as follows: T-CEA-0, post-CEA <= 5 ng/mL and pT1-3; T-CEA-1, post-CEA > 5 ng/mL or pT4; T-CEA-2, post-CEA > 5 ng/mL and pT4.ResultsThe T-CEA scores of the 587 patients were as follows: T-CEA-0 (n = 436; 74%), T-CEA-1 (n = 129; 22%), and T-CEA-2 (n = 10; 2%). The 5-year recurrence-free survival (RFS) rates of the T-CEA-0, 1, and 2 groups were 80.3%, 54.8%, and 0%, respectively (P < 0.01), and the 5-year overall survival (OS) rates were 90.9%, 74.2%, and 0%, respectively (T-CEA-0 vs T-CEA-1: P < 0.01, T-CEA-1 vs T-CEA-2: P = 0.04). Multivariate analysis revealed that an elevated T-CEA score of 1 or 2 was a significant risk factor for poor RFS (HR: 2.89, P < 0.01) and OS (HR: 2.85, P < 0.01).ConclusionThe T-CEA score is a reliable and convenient prognostic score for stage II-III CRC.
引用
收藏
页码:890 / 898
页数:9
相关论文
共 36 条
[21]   Development and validation of prognostic nomograms based on De Ritis ratio and clinicopathological features for patients with stage II/III colorectal cancer [J].
Fu, Jinming ;
Du, Fenqi ;
Tian, Tian ;
Huang, Hao ;
Zhang, Lei ;
Li, Dapeng ;
Liu, Yupeng ;
Zhang, Ding ;
Gao, Lijing ;
Zheng, Ting ;
Liu, Yanlong ;
Zhao, Yashuang .
BMC CANCER, 2023, 23 (01)
[22]   Prognostic significance of high triglyceride and apolipoprotein B levels in patients with stage III and high-risk stage II colorectal cancer undergoing curative surgery [J].
Chen, Xiu-Qing ;
Wu, Pei-Wen ;
Liu, Dong-Hui ;
Yan, Sun-Jie ;
Shen, Xi-Mei ;
Yang, Li-Yong .
ONCOLOGY LETTERS, 2020, 20 (01) :705-714
[23]   Effect of oxaliplatin in elderly colon cancer patients with pathological T4 and/or N2 disease: a multicenter, propensity score-matched analysis [J].
Tominaga, Tetsuro ;
Nonaka, Takashi ;
Oyama, Shosaburo ;
Shiraishi, Toshio ;
Takeshita, Hiroaki ;
Hisanaga, Makoto ;
Fukuoka, Hidetoshi ;
Fukuda, Akiko ;
Sumida, Yorihisa ;
Hashimoto, Shintaro ;
To, Kazuo ;
Tanaka, Kenji ;
Sawai, Terumitsu ;
Nagayasu, Takeshi .
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2022, 37 (05) :1181-1188
[24]   The Prognostic Significance of Postoperative Adjuvant Chemotherapy in the Population Aged 75 Years and Older with Stage II-III Colorectal Cancer: A Retrospective Multi-Center Cohort Study [J].
Liu, Lizhu ;
Pang, Xiaolin ;
Zhao, Ke ;
Chen, Yaxue ;
Li, Yanli ;
You, Ruimin ;
Xu, Tingting ;
Liu, Mengmei ;
Wu, Lin ;
Li, Zhenhui ;
Pu, Hongjiang .
INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2023, 16 :3311-3322
[25]   Clinical significance of the modified Naples prognostic score in patients with stage II-III colon cancer undergoing curative resection: a retrospective study from the real world [J].
Li, Xiaopeng ;
Cheng, Chen ;
Huo, Xiongwei ;
Zhao, Chenye ;
Yuan, Hang ;
Chen, Gang ;
Yu, Junhui ;
Mu, Mingchao ;
Sun, Xuejun .
FRONTIERS IN ONCOLOGY, 2024, 14
[26]   Prognostic implications of T stage in different pathological types of colorectal cancer: an observational study using SEER population-based data [J].
Yao, Nan ;
Li, Wenqiang ;
Wang, Jiwei ;
Chu, Hongyuan ;
Duan, Ning ;
Niu, Xinyu ;
Yu, Guoyong ;
Qu, Jun .
BMJ OPEN, 2024, 14 (02)
[27]   Efficacy and safety of neoadjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and levofolinate for T3 or T4 stage II/III rectal cancer: the FACT trial [J].
Koike, Junichi ;
Funahashi, Kimihiko ;
Yoshimatsu, Kazuhiko ;
Yokomizo, Hajime ;
Kan, Hayato ;
Yamada, Takeshi ;
Ishida, Hideyuki ;
Ishibashi, Keiichiro ;
Saida, Yoshihisa ;
Enomoto, Toshiyuki ;
Katsumata, Kenji ;
Hisada, Masayuki ;
Hasegawa, Hirotoshi ;
Koda, Keiji ;
Ochiai, Takumi ;
Sakamoto, Kazuhiro ;
Shiokawa, Hiroyuki ;
Ogawa, Shimpei ;
Itabashi, Michio ;
Kameoka, Shingo .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (03) :519-525
[28]   T-cell leukemia/lymphoma-1A predicts the clinical outcome for patients with stage II/III colorectal cancer [J].
Li, Hao ;
Yan, Xuebing ;
Liu, Liguo ;
Huang, Linsheng ;
Yin, Mingming ;
Pan, Cheng ;
Zhang, Peng ;
Qin, Huanlong .
BIOMEDICINE & PHARMACOTHERAPY, 2017, 88 :924-930
[29]   Effect of oxaliplatin in elderly colon cancer patients with pathological T4 and/or N2 disease: a multicenter, propensity score-matched analysis [J].
Tetsuro Tominaga ;
Takashi Nonaka ;
Shosaburo Oyama ;
Toshio Shiraishi ;
Hiroaki Takeshita ;
Makoto Hisanaga ;
Hidetoshi Fukuoka ;
Akiko Fukuda ;
Yorihisa Sumida ;
Shintaro Hashimoto ;
Kazuo To ;
Kenji Tanaka ;
Terumitsu Sawai ;
Takeshi Nagayasu .
International Journal of Colorectal Disease, 2022, 37 :1181-1188
[30]   Predictive Value of Postoperative Peripheral CD4+T Cells Percentage in Stage I-III Colorectal Cancer: A Retrospective Multicenter Cohort Study of 1028 Subjects [J].
Li, Zhenhui ;
Li, Shaoyou ;
Liang, Yun ;
Pu, Hongjiang ;
Tu, Changling ;
Wu, Zhenyu ;
You, Dingyun .
CANCER MANAGEMENT AND RESEARCH, 2020, 12 :5505-5513